Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Complete Title: A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF INTRAVENOUSLY ADMINISTERED FHD-609 IN SUBJECTS WITH ADVANCED SYNOVIAL SARCOMA
Trial Phase: I
Investigator: Michael Wagner, MD
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma or advanced SMARCB1-loss tumors.
Keywords:
- Sarcoma, Synovial
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
I
Michael Wagner, MD
RG1122014
NCT04965753
A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF INTRAVENOUSLY ADMINISTERED FHD-609 IN SUBJECTS WITH ADVANCED SYNOVIAL SARCOMA
Sarcoma, Synovial